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dDITORIAL COMMENT
urgery, Angioplasty,
r Medical Therapy for
ymptomatic Multivessel
oronary Artery Disease
s There an Indisputable
Winning Strategy” From
vidence-Based Clinical Trials?*
illiam E. Boden, MD, FACC
artford and Farmington, Connecticut
e all like to embrace winning strategies for patient
anagement in cardiovascular therapeutics. These strategies
re important because we are so often besieged with a
pectrum of treatment options, and both patients and their
amilies, as well as referring physicians, implicitly put their
rust in our specialized knowledge to make well-informed
ecisions that impact favorably both symptomatic improve-
ent (quality of life) and event-free survival (quantity of
ife). The optimal management of stable angina patients
ith symptomatic multivessel coronary artery disease
CAD) remains multi-dimensional, but therapeutic options
nclude aggressive medical therapy, percutaneous coronary
ntervention (PCI), or coronary artery bypass graft (CABG)
urgery.
See page 1743
What can we learn from the wealth of randomized
linical trials over the past 30 years that have rigorously
valuated myocardial revascularization (CABG or PCI) as
n initial treatment strategy compared with medical ther-
py in stable CAD patients and, can we identify treatment
trategies that are clear winners—or losers?
In the 1970s, the role of CABG surgery versus medical
herapy (largely nitrates and/or beta-blockers) was assessed
rospectively in three separate multicenter, randomized
linical trials (RCTs): the Veterans Administration Coop-
rative Study of patients with chronic stable angina (1), the
uropean Coronary Surgery Study (2), and the Coronary
rtery Surgery Study (3). On the basis of these pivotal trials,
e can conclude convincingly that CABG surgery is the
reatment of choice for patients with significant obstruction
f the left main coronary artery, triple-vessel CAD and left
entricular (LV) systolic dysfunction, and two-vessel CAD
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiology, the Henry Low Heart Center at Hartford
ospital, Hartford, Connecticut; and the University of Connecticut School ofwedicine, Farmington, Connecticut.lus proximal left anterior descending coronary artery
LAD) stenosis (1–3); not only was CABG surgery superior
o conventional (1970s) medical therapy for angina relief, it
lso conferred a significant survival advantage. Moreover, a
eta-analysis of the three major trials and some smaller
nes showed a significant survival benefit for patients with
riple-, double-, or even single-vessel CAD patients that
ncluded a proximal LAD stenosis, with or without abnor-
al LV function (4). Thus, we can say that, for many CAD
atients with stable angina, CABG surgery compared with
edical therapy improves both the quality and quantity of
ife. Coronary artery bypass graft surgery is a clear winner . . .
Percutaneous coronary intervention has become almost
niversally embraced as the preferred revascularization strat-
gy for CAD patients in the U.S., where now more than 1
illion such procedures are performed annually. No less
han 10 RCTs have evaluated PCI versus CABG surgery as
n initial strategy of managing stable angina patients and
ome have reported long-term results (5–7). Overall, these
rials suggest that PCI is slightly less effective at relieving
ngina than is CABG surgery, but there is no compelling
vidence that either revascularization strategy provides a
rognostic advantage (i.e., reduces significantly the inci-
ence of myocardial infarction [MI] or death) in the
ajority of CAD patients. More recently, several trials of
ultivessel stenting versus CABG surgery have shown
omparable results to earlier studies of balloon angioplasty
ersus surgery and suggest that certain subsets of patients,
otably diabetics, may benefit from stenting, but their
ollow-up periods are still relatively short. And even with
he recent introduction of drug-eluting stents, there is a
aucity of data in many subsets of CAD patients (i.e.,
iabetics, those with small coronary vessel diameter, com-
lex anatomy, and so on) and virtually no long-term data to
ssess the efficacy and durability of these newer technologic
dvances on reducing “hard” clinical end points. Thus, at
resent, PCI for patients with multivessel CAD cannot be
onsidered a clear “winner” compared with CABG surgery.
ut, what about PCI or CABG surgery compared with
edical therapy in such patients?
In this issue of the Journal, Hueb et al. (8) report the
ne-year follow-up results of the second Medicine, Angio-
lasty, or Surgery Study (MASS-II), which randomized 611
table angina patients with multivessel CAD to CABG
urgery, PCI, or medical therapy. In this relatively small,
ingle-site study, the authors demonstrated a statistically
ignificant lower rate of one-year mortality in the medical
herapy group (1.5%), whereas the death rates for the PCI
4.5%) and CABG surgery (4.0%) groups were comparable.
he rate of subsequent Q-wave MI at one year was highest
n the PCI group (8.3%), lowest in the CABG group
2.0%), and intermediate in the medical therapy group
5.0%). Rates of event-free survival (freedom from cardiac
eath, MI, or refractory angina requiring revascularization)
ere significantly different (p  0.0001) among the three
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May 19, 2004:1752–4 Editorial Commentroups: CABG event-free survival  93%, medical therapy
vent-free survival  88%, and PCI event-free survival 
6% (8). Freedom from angina at one year was significantly
igher among CABG-treated patients (61%) compared
ith medically treated patients (36%), but was not signifi-
antly different from PCI-treated patients (55%), while the
eed for subsequent revascularization was significantly
reater among those who underwent PCI compared with
ABG or medically treated patients—with the need for
epeat PCI being the major “driver.”
The MASS-II data are provocative and suggest strongly
hat a routine strategy of PCI for patients with mild-to-
oderate angina and multivessel CAD patients is not
uperior to CABG surgery or medical therapy, and may be
ssociated with lower rates of event-free survival. While
CI may be comparable to CABG surgery for angina relief,
he MASS-II trial results suggest that PCI does not appear
o be a “clear winner” with respect to reducing long-term
one year) clinical events in stable angina patients.
What is the relevance of the MASS-II trial to contem-
orary clinical practice? Fundamentally, there are two rea-
ons to recommend PCI in angina patients: 1) for symptom
elief, when medical therapy is ineffective; and 2) to improve
rognosis. Importantly, for a significant percentage of an-
ina patients, revascularization is not considered essential
or either symptom relief or prognostic reasons. In fact,
any patients with CAD do not have debilitating symp-
oms, and the data to support revascularization in these have
ndergone less rigorous study, yet there are many CAD
atients without refractory or debilitating symptoms who
ack the prognostic indicators mandating revascularization
i.e., objective evidence of inducible ischemia, LV dysfunc-
ion, and so on) (9). Despite this, millions of these patients
re undergoing PCI/stenting all over the world while the
vidence-based value of that approach has been sparse (9).
Why is this the case? Most probably, physician preference
nd societal expectation may play an important part—at
east in the U.S. Many clinical and interventional cardiolo-
ists advocate prophylactic dilation of significant coronary
tenoses irrespective of symptoms or compelling evidence of
schemia, in the belief that this reduces the risk of progres-
ion to coronary occlusion, prevents MI, or improves prog-
osis. Yet, published data—notably the recent seven-year
utcomes data from the Randomised Intervention Treat-
ent of Angina (RITA)-2 trial (10)—do not support this
elief, because dilation of one or more coronary stenoses did
ot subsequently affect the incidence of MI or death over
his long-term period of follow-up.
Nonetheless, many physicians approach CAD patient
anagement based largely on angiographic findings and
ccept the premise that an “oculostenotic reflex” inevitably
eads to an obligate “oculodilatory reflex.” Moreover, as
ing (9) emphasizes, the corollary of this clinical practice is
he impact it has on patient/family perception and decision-
aking; patients who are told they have a “blockage” oftenisplay an “auditory-stenotic reflex,” namely, “if it is
locked, I want it fixed.”
Finally, in comparing PCI with medical therapy, several
mall trials have compared PCI with various medical ther-
py strategies in stable angina patients with both single-
essel and multivessel CAD, but most have reported only
imited follow-up data (10–12). Overall, compared with
edical therapy, these trials show that PCI significantly
mproved angina relief and short-term exercise tolerance,
ut did not significantly reduce death, MI, or need for
ubsequent revascularization. In a meta-analysis of six
CTs (13) from 1979 to 1998, comprising 1,904 patients
Fig. 1), the only outcome measure that favored PCI
ompared with medical therapy was angina relief (odds ratio
OR] 0.70; 95% confidence interval [CI] 0.50 to 0.98). For
he end points of death, MI, and need for repeat PCI, the
Rs trended strongly in favor of medical therapy (29% to 42%
etter than PCI), while the need for subsequent CABG was
lmost 60% less likely among medically treated patients
13). However, except for this CABG comparison, the CIs
urrounding the other point estimates were wide, owing to
he relatively small sample sizes.
Clearly, such a meta-analysis (13) of underpowered stud-
es cannot be considered in any way definitive, but unlike
he prognostic advantage afforded by CABG surgery in
any subsets of CAD patients with stable angina pectoris,
here is no compelling evidence from among the more than
5 RCTs (13,14) to date that PCI with stenting is superior
o standard balloon angioplasty, CABG surgery, or medical
herapy with respect to reducing the “hard” end points of
eath or MI. For the end point of angina relief, PCI appears
o be better than medical therapy and probably the same as
ABG surgery. Thus, PCI appears to favorably affect
uality of life only and not prognostically important event-
ree survival.
igure 1. Risk ratios and 95% confidence intervals (CI) for percutaneous
ransluminal coronary angioplasty (PTCA) versus medical therapy among
he randomized clinical trials in patients with stable angina and coronary
rtery disease. End points of interest include angina relief, fatal and
on-fatal myocardial infarction, death, need for subsequent coronary artery
ypass graft (CABG) surgery and subsequent PTCA. Reprinted, with
ermission, from Brophy et al. (14).Therefore, treatment choice should be guided by symp-
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Editorial Comment May 19, 2004:1752–4om status and severity. The majority of patients with
ild-to-moderate angina can be safely managed medically,
ut PCI is appropriate if symptoms are not adequately
ontrolled by medication or if other high-risk features are
pparent.
Lastly, the results of the Clinical Outcomes Utiliz-
ng Revascularization and Aggressive druG Evaluation
COURAGE) trial in almost 2,300 CAD patients may
larify further whether PCI combined with aggressive,
ultifaceted medical therapy is superior to intensive medi-
al therapy alone on the long-term clinical events of death,
I, or troponin-positive acute coronary syndromes during a
.5- to 7-year (average, 4.5 years) follow-up. The COUR-
GE trial seeks to advance the paradigm that the best
linical outcomes can be achieved by coupling PCI with
ntensive, guideline-driven medical therapy, and the hy-
othesis of COURAGE is that such a combined approach
ill be superior to a medical therapy-only strategy in
atients with symptomatic multivessel CAD. Enrollment in
he COURAGE trial has now concluded and follow-up is
nderway until at least mid-2006. Regardless of the clinical
utcome, however, COURAGE promises to be an impor-
ant, landmark trial that will shed much-needed light on
lucidating the best therapeutic approach to managing
illions of angina patients in the U.S. and worldwide, and
t will add to the growing body of scientific studies, such as
ITA-2 and MASS-II, in better defining treatment op-
ions—and perhaps the best “winning strategy”—for both
atients and physicians.
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irector, Division of Cardiology, Hartford Hospital, 80 Seymour
treet, Hartford, Connecticut 06102-5037. E-mail: wboden@
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